NCT05649475 is a clinical trial in Stage I-III Breast Cancer, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

Who is sponsoring NCT05649475?

NCT05649475 is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

What condition does NCT05649475 study?

NCT05649475 studies Stage I-III Breast Cancer.

Is NCT05649475 still recruiting?

NCT05649475 is currently status unknown. Last updated 24 February 2023.

Last reviewed 2023-02-24 · How we verify

NCT05649475

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Circulating Tumor DNA Monitoring in Breast Cancer Undergoing Neoadjuvant Therapy

Status unknown Last updated 24 February 2023

What this trial tests

trial in Stage I-III Breast Cancer in 100 participants. Status unknown.

Timeline

31 August 2021

Primary endpoint
31 July 2024

31 July 2025

Quick facts

Lead sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	100
Start date	31 August 2021
Primary completion	31 July 2024
Estimated completion	31 July 2025
Sites	1 location across China

Conditions studied

Stage I-III Breast Cancer — all drugs for Stage I-III Breast Cancer →

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Who can join

18 and older, any sex, with Stage I-III Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In the prospective, open, observational study, we aim to evaluate whether circulating tumor DNA (ctDNA) can be the marker of the response to neoadjuvant therapy in stage I-III breast cancer.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Circulating Tumor DNA in the Management of Early-Stage Breast Cancer.
Vlataki K, Antonouli S, Kalyvioti C, Lampri E, et al · · 2023 · cited 23× · PMID 37371043 · DOI 10.3390/cells12121573

Verify or expand the search:

Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials

Trials by the same sponsor.

NCT07445152 — Research on Construction and Verification of Multimodal Medical Imaging Large Model · not yet recruiting
NCT06775665 — A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population · not yet recruiting
NCT07533422 — Rescue Reatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing · NA · not yet recruiting
NCT07487285 — A Non-inferiority Study of Laser Combined With Ultrasonic Debridement Therapy (LCUDT) Versus Manual Combined With Ultras · NA · not yet recruiting
NCT07505186 — Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05649475 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital, School of Medicine, Zhejiang University
Last refreshed: 24 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05649475.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing